oth angiotensin-converting enzyme inhibitors (ACEIs) and ngiotensin receptor blockers (ARBs) are largely used worldide as effective treatment of blood hypertension and ther cardiovascular diseases, including congestive heart ailure and diabetic nephropathy. For instance, in 2011 there ere 164 million prescriptions of ACEIs and 86 million precriptions of ARBs in US.1 Generally, these drugs are w...

Abstract Background While hypertension is the most common comorbid condition in patients with coronavirus disease 2019 (COVID-19) Korea, there a lack of studies investigating risk factors COVID-19 Korea. In this study, we aimed to examine effects hypertensive Korean patients. Methods We selected from database project #OpenData4Covid19. This information was linked their 3-year historical healthc...

BACKGROUND In April/2009, the UK National Health Service initiated four Better Care Better Value (BCBV) prescribing indicators, one of which encouraged the prescribing of cheaper angiotensin-converting enzyme inhibitors (ACEIs) instead of expensive angiotensin receptor blockers (ARBs), with 80 % ACEIs/20 % ARBs as a proposed, and achievable target. The policy was intended to save costs without ...

OBJECTIVE/HYPOTHESIS Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) have been shown to suppress expression of periostin, a matricellular protein that is markedly elevated in nasal polyp tissue. The purpose of this study was to determine whether use of these antihypertensive agents affects the time to revision sinus surgery in patients with polyp regrow...

Assuming that blood pressure is lowered equivalently, diuretics are more effective than angiotensin-converting enzyme inhibitors (ACEIs), calcium channel blockers (CCBs), and alpha-adrenergic receptor blockers (alpha-blockers) at preventing heart failure, and they are more effective than ACEIs and alpha-blockers at preventing strokes. Compared with beta-adrenergic receptor blockers (beta-blocke...

Renin–angiotensin–aldosterone system (RAAS) inhibition has become the cornerstone of evidence-based therapies in cardiovascular disease, including patients with hypertension, high cardiovascular risk, left ventricular dysfunction after myocardial infarction, and heart failure with reduced ejection fraction (1–3). Both angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor ...

BACKGROUND The objective of this meta-analysis was to evaluate the risk of anemia in patients who received renin-angiotensin system (RAS) inhibitors. METHODS A literature search was performed using MEDLINE, EMBASE, and Cochrane Database of Systematic Reviews from inception through November, 2014. Studies that reported relative risks, odd ratios or hazard ratios comparing the anemia risk in pa...

Angiotensin-converting enzyme inhibitors (ACEIs) are among the most prescribed and effective medicinal products for treatment of several cardiovascular diseases. According to a number studies, 30% patients taking ACEIs develop adverse drug reactions (ADRs), discontinuation is often required as result. The common ADR associated with dry (non-productive) cough. Nevertheless, clinical signs medica...

Despite of well‐established clinical advantages of angiotensin converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) among hemodialysis patients, they are seldom prescribed. The prevalence of end‐stage renal disease (ESRD) is increasing in India due to diabetes, hypertension, and ageing population. Hypertension is major morbidity affecting 90% of patients on hemodialy...

PURPOSE To investigate the incidence and clinical characteristics of angioedema associated with the use of angiotensin-converting enzyme inhibitors (ACEIs) in an outpatient allergy department. METHODS A retrospective review of medical records of new patients seen in an allergy clinic. Demographic and clinical data of patients with ACEI-induced angioedema were analyzed. RESULTS Nine (0.37%) ...